Carola Grinninger

Learn More
BACKGROUND Long-term results of prospective randomized trials comparing triple immunosuppressive strategies combining tacrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart transplantation (HTX) are rarely published. Therefore, we collected long-term follow-up data of an intervention cohort 10 years after(More)
Heart transplantation, which was first performed in 1967 [1], is now an accepted treatment for end-stage heart failure. Nowadays, half of the heart transplanted patients have lost their own organ function as a consequence of atherosclerosis due to ischemic cardiomyopathy (ICM) [2]. The registry data of the International Society for Heart and Lung(More)
BACKGROUND Lung transplantation for end-stage pulmonary disease is an established procedure and the number of transplantations is increasing worldwide even in developing countries. Usually donor lungs are transported in an inflated state and the bronchi are closed with a stapler device. CASE REPORT We present a technique that avoids costly stapler devices(More)
a Department of Prevention, Rehabilitation and Sports Medicine, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, Germany b Department of Cardiac Surgery, Klinikum Grosshadern, Ludwig-Maximilians-Universität München (LMU), Munich, Germany c DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich,(More)
BACKGROUND Although acute cellular rejection after heart transplantation (HTX) can be controlled by full-dose calcineurin inhibitor (CNI)-based immunosuppressive regimens, cardiac allograft vasculopathy (CAV), nephrotoxicity, and malignancy remain ongoing problems. To evaluate the potential beneficial effects of sirolimus and CNI reduction, we compared de(More)
BACKGROUND Despite improvements in immunosuppressive therapy, the most advantageous combination for cardiac transplant recipients has not been established. This randomized controlled trial was performed to evaluate the efficacy and safety of 3 immunosuppressive protocols. METHODS Between 2003 and 2005, 78 de novo cardiac transplant recipients were(More)
In recent years a series of trials has sought to define the optimal protocol for everolimus-based immunosuppression in heart transplantation, with the goal of minimizing exposure to calcineurin inhibitors (CNIs) and harnessing the non-immunosuppressive benefits of everolimus. Randomized studies have demonstrated that immunosuppressive potency can be(More)
  • 1